Latest Dorsavi (ASX:DVL) News

A small-cap tech week where one US gaming platform build lit the fuse, while a big semiconductor raise kept sliding after the halt. Deals and contracts did the heavy lifting, but several “open higher, finish lower” sessions showed buyers are still picky.

dorsaVi has commenced development of Sensor V6.5, a firmware upgrade that embeds intelligence directly within its wearable sensors, reducing latency and paving the way for future neuromorphic computing integration.

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Tech microcaps swung hard as funding news, contract wins and disclosure issues collided. The biggest falls came where investors saw either forced selling or more cash needs ahead.

dorsaVi has initiated early-stage evaluation of resistive RAM (RRAM) test chips, marking a key step toward an advanced 22-nm memory platform designed to meet rising AI-driven demands in edge computing.

A single trading halt lit a fire under one small-cap, while a string of fundraisings reminded investors how often growth still needs fresh cash. Elsewhere, “AI-first” is splitting into two camps: products that ship now, and stories that still need proof.

dorsaVi has formed a world-class Technical Advisory Board to accelerate its pioneering ‘Intelligence at the Ultra Edge’ strategy, integrating advanced memory and neuromorphic computing into robotics and healthcare devices.

DorsaVi Limited reported a steep increase in its half-year loss to $3.6 million, driven by declining revenues and a sharp rise in operating costs, despite raising over $5 million in fresh capital.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

dorsaVi has launched a multi-year collaboration with leading Asian research institutes to develop its proprietary RRAM technology at the 22-nanometer node, targeting AI-driven robotics and wearable applications.